| Note | Three TrkB isoforms are reported by UniProt/Swiss-Prot:
1. The long isoform TrkB, including the tyrosine kinase domain (ID Q16620-1; variant c).
2. The truncated isoform TrkB-T1 lacking the tyrosine kinase domain (ID Q16620-2; variant b).
3. The truncated isoform TrkB-T-Shc lacking the tyrosine kinase domain but retaining the Shc site (ID Q16620-3; variant e). |
| |
| |  |
| |
| | The predicted domains of TrkB (variant c): Signal Peptide (SP, AA 1-31); Leucine Rich Repeat N-Terminal domain (LRRNT, AA 31-65); Leucine-rich Repeats (LRR, AA 72-93, 96-117, 116-138); Leucine Rich Repeat C-Terminal domain (LRRCT, AA 148-195); Immunoglobulin C-2 Type 1 domain (IGC2-1, AA 197-282); Immunoglobulin C-2-type 2 domain (IGC2-2, AA 295-365); Transmembrane (TM, AA 431-454); the Protein Kinase domain (TyrKc, AA 538-807). In addition the site of interaction with SHC1 (Shc, AA 516) and with Phospho-Lipase C-gamma-1 (AA PLC-gamma, 817) are indicated. |
| |
| Description | The unprocessed precursor of the full-length TrkB (a) consists of 838 AA. Variant (c) excludes 16 AA of unknown function, located downstream of the transmembrane segment.
The N-terminal portion (AA 32-430) is potentially extracellular and includes several N-glycosylation sites (AA 67, 121, 254). It follows a single transmembrane segment (AA 432-454). The C-terminal portion is cytosolic (AA 455-822) and comprises the Protein Kinase domain. This region includes the ATP binding site (AA 544-552) and several sites of autophosphorylation such as Tyr-516/702/706/707/817 (AA position refers to variant c).
The truncated Trkb-T1 (b) is composed of 477 AA. TrkB-T-Shc variants d and e consist of 553 AA and 537 AA, respectively. Truncated isoforms TrkB-T1 and TrkB-T-Shc include C-terminal sequence variations of 10 and 9 AA, respectively. |
| Expression | NTRK2 gene is preferentially expressed in brain, spinal cord, cranial and spinal ganglia. Expression is most prominent in the following brain regions: amygdale, caudate nucleus, cerebellum, choroid plexus, corpus callosum, cortex, hippocampus, hypothalamus and thalamus. In addition, a variety of cranial structures such as eyes, ophthalmic nerves, various facial districts and vestibular system indicate significant expression. Lower expression is described in several other tissues such as heart, kidney, lung, ovaries, pancreas, pituitary gland, prostate, salivary glands, skeletal muscle, spleen, thymus and thyroid.
Isoforms TrkB and TrkB-T1 are expressed in brain as well as in several peripheral areas, whereas TrkB-T-Shc is primarily expressed in brain.
AceView (NCBI) analysis of cDNA clones supports the expression pattern suggested by the evaluation of mRNA described above. In addition suggests elevated expression in several tumor tissues. |
| Localisation | Neuronal activity promotes TrkB translocation from intracellular vesicles to the plasma membrane where it becomes available for neurotrophins. The N-terminal segment is extracellular and is involved in neurotrophin binding and cell adhesion. A single transmembrane segment is located in the central portion of the polypeptide. The C-terminal segment is intracellular and comprises the protein kinase domain. |
| Function | TrkB specifically binds brain-derived neurotrophic factor (BDNF) and neurotrophin4/5. It can also bind neurotrophin-3 with low affinity but it excludes nerve growth factor (NGF). Neurotrophin binding triggers receptor dimerization and consequent trans-phosphorylation of tyrosine residues of the TyrKc domain. Phosphorylated receptor undergoes conformational changes, which promote the recruitment of intracellular substrates such SHC1, PI-3 kinase, and PLC-gamma-1. The signaling cascades consequently activated support neuronal survival during development and following injuries, promote neuronal differentiation and maintenance, control short-term and long-term synaptic activity. TrkB can also form heterodimers with the pan-neurotrophin receptor p75NTR or with truncated TrkB. This influences the establishment of specific connections with signaling pathways. |
| Homology | TrkB belongs to the large family of protein kinase comprising a conserved kinase domain. It is included in the subfamily of tyrosine protein kinase. For the presence of a highly conserved intracellular TyrKc domain it is most related to growth factor receptors, and particularly to the neurotrophic factor receptors TrkA and TrkC. The homology with tyrosine kinase receptors is extended to the IGC-2 and LRRs domains, however, these are also present in cell-adhesion molecules. |
| trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. |
| Klein R, Parada LF, Coulier F, Barbacid M |
| The EMBO journal. 1989 ; 8 (12) : 3701-3709. |
| PMID 2555172 |
| |
| Signal transduction by receptors with tyrosine kinase activity. |
| Ullrich A, Schlessinger J |
| Cell. 1990 ; 61 (2) : 203-212. |
| PMID 2158859 |
| |
| A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors. |
| Schneider R, Schweiger M |
| Oncogene. 1991 ; 6 (10) : 1807-1811. |
| PMID 1656363 |
| |
| The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. |
| Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J, Burton LE, Stanton BR, Kaplan DR, Hunter T |
| Cell. 1991 ; 65 (5) : 895-903. |
| PMID 1645620 |
| |
| trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. |
| Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C, Glass DJ, Masiakowski P, Furth ME, Valenzuela DM |
| Cell. 1991 ; 65 (5) : 885-893. |
| PMID 1710174 |
| |
| Identification of TrkB autophosphorylation sites and evidence that phospholipase C-gamma 1 is a substrate of the TrkB receptor. |
| Middlemas DS, Meisenhelder J, Hunter T |
| The Journal of biological chemistry. 1994 ; 269 (7) : 5458-5466. |
| PMID 8106527 |
| |
| Expression and function of TRK-B and BDNF in human neuroblastomas. |
| Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM |
| Molecular and cellular biology. 1994 ; 14 (1) : 759-767. |
| PMID 8264643 |
| |
| Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). |
| Nakagawara A, Liu XG, Ikegaki N, White PS, Yamashiro DJ, Nycum LM, Biegel JA, Brodeur GM |
| Genomics. 1995 ; 25 (2) : 538-546. |
| PMID 7789988 |
| |
| Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. |
| Aoyama M, Asai K, Shishikura T, Kawamoto T, Miyachi T, Yokoi T, Togari H, Wada Y, Kato T, Nakagawara A |
| Cancer letters. 2001 ; 164 (1) : 51-60. |
| PMID 11166915 |
| |
| Analysis of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. |
| Stoilov P, Castren E, Stamm S |
| Biochemical and biophysical research communications. 2002 ; 290 (3) : 1054-1065. |
| PMID 11798182 |
| |
| Mutational analysis of the tyrosine kinome in colorectal cancers. |
| Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE |
| Science (New York, N.Y.). 2003 ; 300 (5621) : page 949. |
| PMID 12738854 |
| |
| Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. |
| Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS |
| Nature. 2004 ; 430 (7003) : 1034-1039. |
| PMID 15329723 |
| |
| A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. |
| Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, O'Rahilly S, Farooqi IS |
| Nature neuroscience. 2004 ; 7 (11) : 1187-1189. |
| PMID 15494731 |
| |
| The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. |
| Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L |
| Carcinogenesis. 2005 ; 26 (12) : 2105-2115. |
| PMID 16051641 |
| |
| p75NTR--live or let die. |
| Nykjaer A, Willnow TE, Petersen CM |
| Current opinion in neurobiology. 2005 ; 15 (1) : 49-57. |
| PMID 15721744 |
| |
| Contribution of NTRK2 to the genetic susceptibility to anorexia nervosa, harm avoidance and minimum body mass index. |
| Ribases M, Gratacos M, Badia A, Jimenez L, Solano R, Vallejo J, Fernandez-Aranda F, Estivill X |
| Molecular psychiatry. 2005 ; 10 (9) : 851-860. |
| PMID 15838534 |
| |
| Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. |
| Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, Zhang W, Fidler IJ, Chiao PJ |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 ; 11 (2 Pt 1) : 440-449. |
| PMID 15701826 |
| |
| Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. |
| Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB |
| Genes, chromosomes & cancer. 2005 ; 44 (3) : 279-291. |
| PMID 16015647 |
| |
| Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. |
| Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ |
| Cancer research. 2006 ; 66 (8) : 4249-4255. |
| PMID 16618748 |
| |
| Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. |
| Geiger TR, Peeper DS |
| Cancer research. 2007 ; 67 (13) : 6221-6229. |
| PMID 17616679 |
| |
| Neurotrophic receptor TrkB: Is it a predictor of poor prognosis for carcinoma patients? |
| Han L, Zhang Z, Qin W, Sun W |
| Medical hypotheses. 2007 ; 68 (2) : 407-409. |
| PMID 17008023 |
| |
